Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $27.00.
NRIX has been the subject of several research reports. Royal Bank of Canada increased their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Friday, July 12th. Needham & Company LLC lowered their price objective on Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday, July 12th. JPMorgan Chase & Co. upped their price objective on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a report on Monday, July 15th. Barclays lifted their target price on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Finally, HC Wainwright upped their price target on shares of Nurix Therapeutics from $19.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, June 18th.
Read Our Latest Research Report on Nurix Therapeutics
Insiders Place Their Bets
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. ProShare Advisors LLC lifted its position in Nurix Therapeutics by 9.1% during the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after purchasing an additional 998 shares during the last quarter. ClariVest Asset Management LLC boosted its stake in Nurix Therapeutics by 2.9% in the second quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock worth $1,318,000 after buying an additional 1,766 shares in the last quarter. Public Employees Retirement System of Ohio grew its position in Nurix Therapeutics by 3.7% during the first quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock valued at $747,000 after acquiring an additional 1,820 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Nurix Therapeutics by 299.8% during the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after acquiring an additional 3,424 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Nurix Therapeutics by 67.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock worth $138,000 after acquiring an additional 3,793 shares during the last quarter.
Nurix Therapeutics Stock Performance
Shares of NASDAQ:NRIX opened at $21.54 on Thursday. Nurix Therapeutics has a fifty-two week low of $4.22 and a fifty-two week high of $26.31. The company’s 50-day moving average is $23.18 and its 200 day moving average is $18.97. The company has a market capitalization of $1.06 billion, a P/E ratio of -7.38 and a beta of 2.22.
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last released its earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.08). Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. The company had revenue of $12.09 million during the quarter, compared to analysts’ expectations of $19.35 million. As a group, research analysts predict that Nurix Therapeutics will post -2.95 earnings per share for the current year.
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Recommended Stories
- Five stocks we like better than Nurix Therapeutics
- What Does a Stock Split Mean?
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- How to Use the MarketBeat Dividend Calculator
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- The Role Economic Reports Play in a Successful Investment Strategy
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.